A comprehensive analysis examines a biological sample to detect the presence of seventeen distinct classes of drugs or their metabolites. This type of screening offers a broad overview of substance use, identifying a wider range of potentially abused substances compared to less extensive panels. For instance, such a test might include assays for amphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine (PCP), tetrahydrocannabinol (THC), methadone, propoxyphene, tricyclic antidepressants, and others.
The utilization of expanded drug screenings offers several advantages. It provides a more complete picture of an individual’s potential substance use, aiding in accurate diagnosis and informed treatment decisions. Furthermore, its comprehensive nature can deter substance abuse by increasing the likelihood of detection. Historically, the expansion of drug testing panels has been driven by the emergence of new synthetic drugs and evolving patterns of substance abuse, requiring more sophisticated methods of detection.